Genmab A/S (NASDAQ:GMAB) Sees Large Volume Increase – Still a Buy?

Genmab A/S (NASDAQ:GMAB) saw unusually-high trading volume on Thursday . Approximately 470,144 shares were traded during mid-day trading, a decline of 33% from the previous session’s volume of 705,920 shares.The stock last traded at $20.58 and had previously closed at $20.45.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on GMAB shares. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Wednesday, October 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. Redburn Atlantic started coverage on Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Truist Financial lowered their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Trading Up 0.9 %

The company has a market capitalization of $13.67 billion, a price-to-earnings ratio of 20.05, a P/E/G ratio of 0.64 and a beta of 0.99. The firm has a 50-day simple moving average of $23.16 and a two-hundred day simple moving average of $25.91.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. During the same period last year, the business earned $0.47 earnings per share. Equities research analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. grew its position in Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after buying an additional 544 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Genmab A/S by 123.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after acquiring an additional 1,787 shares in the last quarter. Blue Trust Inc. grew its position in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the period. Headlands Technologies LLC increased its stake in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its stake in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.